Actinium Pharmaceuticals presents progress on ATNM-400 clinical and preclinical cancer research

Traders Union
All News
Business & Wealth
Companies
Actinium unveils oncology research

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Yaroslav Dmytrenko

20.10.2026

Actinium Pharmaceuticals presents progress on ATNM-400 clinical and preclinical cancer research — Actinium unveils oncology research

Actinium Pharmaceuticals presented new updates on the development of ATNM-400 in its clinical program targeting prostate cancer, as well as preclinical research in lung, ovarian, and colorectal cancers.

The company shared its latest findings at EANM26 to a full audience, drawing interest in its ongoing oncology projects.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Actinium previously presented preclinical data for ATNM-400 in lung, colorectal, and ovarian cancer at EANM26 in Vienna, focusing on early-stage efficacy research across multiple models. The company also announced the appointment of Matt David as chief financial officer, adding over two decades of industry and finance experience. Further details are available in Actinium’s ATNM-400 efficacy report and the leadership update.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Actinium

Editor's Picks for You

How China is turning AI credits into Singles’ Day’s newest staple

By Dmytro Kharkov
16 hours ago

How China is turning AI credits into Singles’ Day’s newest staple

Editors' Picks

Banks vs. crypto companies: Who better protects your money from hackers?

By Elena Nikulina
19 hours ago

Banks vs. crypto companies: Who better protects your money from hackers?

Editors' Picks

U.S. elections: What awaits the crypto industry after the Democrats' victory?

By Eugene Komchuk
22 hours ago

U.S. elections: What awaits the crypto industry after the Democrats' victory?

Editors' Picks

All Editors' Top Picks

Latest Actinium News

Actinium Pharmaceuticals to present Actimab-A safety and tolerability data at ASH26

By Hanna Syniavska
16 hours ago

Actinium Pharmaceuticals to present Actimab-A safety and tolerability data at ASH26

Companies

Actinium Pharmaceuticals initiates study of HER3 targeted radiotherapy in prostate cancer

By Mykhailo Ihnatenko
23.10.2026

Actinium Pharmaceuticals initiates study of HER3 targeted radiotherapy in prostate cancer

Companies

Actinium Pharmaceuticals unveils ATNM-400 efficacy data across multiple cancer models

By Daria Chernytska
16.10.2026

Actinium Pharmaceuticals unveils ATNM-400 efficacy data across multiple cancer models

Companies

All Actinium News

Dmytro Kharkov
16 hours ago

How China is turning AI credits into Singles’ Day’s newest staple

Elena Nikulina
19 hours ago

Banks vs. crypto companies: Who better protects your money from hackers?

Eugene Komchuk
22 hours ago

U.S. elections: What awaits the crypto industry after the Democrats' victory?

Anastasiia Chabaniuk
Yesterday

From Coinbase to Visa: Who makes money from blockchain?

Mikhail Vnuchkov
Yesterday

One of the biggest M&A deals: Why is Marvell buying Lumentum?

Alena Volkova
18 min ago

Over €120 million stolen as crypto facilitates laundering, Gregory Raymond reveals

Mykhailo Ihnatenko
38 min ago

Customer Value Fund allows startups to access non-dilutive capital at 12–15% interest, Gokul Rajaram says

Ksenia Gerey
1 hour ago

Ueno Bank freezes access to money for millions, Pushpendra Singh notes

Mykhailo Ihnatenko
1 hour ago

S&P 500 closes 1.65% higher after elections, Afzal Lokhandwala notes

Yaroslav Dmytrenko
1 hour ago

Fred Krueger: Bitcoin CAGR is a misleading metric for investment evaluation

Top News

Olga Shendetskaya
13 min ago

Gold rises above $4,100 as U.S. dollar weakens after midterms

Gold rises above $4,100 as U.S. dollar weakens after midterms

Eugene Komchuk
1 hour ago

Polygon proposes hard fork to recover funds stolen from Binance

Polygon proposes hard fork to recover funds stolen from Binance

Oleksii Zaichenko
16 hours ago

Bitcoin tops $80,500 as U.S. stocks rally after midterm elections

Bitcoin tops $80,500 as U.S. stocks rally after midterm elections

Dmytro Kharkov
16 hours ago

How China is turning AI credits into Singles’ Day’s newest staple

How China is turning AI credits into Singles’ Day’s newest staple

Andrey Mastykin
17 hours ago

Oil extends losses as U.S. midterm results fuel Iran peace hopes

Oil extends losses as U.S. midterm results fuel Iran peace hopes

Top 5 companies for you

United States

Live News

Igor Krasulya
Now

Demand for Meta debut euro bonds exceeds offering size sixfold

Olga Shendetskaya
Now

McDonald's reports first sales decline in 18 months

Anton Kharitonov
Now

EUR/USD tests 1.1270 as U.S. election results and eurozone inflation boost the euro

Mykhailo Ihnatenko
Now

AMD stock jumps over 6% after record earnings and strong Q4 outlook

Eugene Komchuk
Now

Morgan Stanley joins Wall Street asset tokenization initiative

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.